PARMAX PHARMA SHARE PRICE

Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara. The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax`s pharmaceutical operations. The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The Company then discontinued their business activities for few years due to various reasons. Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA. Antibiotic project was fully implemented from 31st May`97. The core segments of the Company comprise of Anti-Infectives, Analgesics & anti-inflammatory; Cardiovascular APIs and General oral formulations (tablets, capsules). Apart from this, the Company works a stable growth in API volumes due to consistent domestic demand. It has marginal increase in pricing due to higher input costs passed on. It has improved the plant utilization especially in Q3 and Q4. It works minor exports to neighboring countries like Bangladesh, Bhutan, Nepal, who do not operate their own sea routes.

Parmax Pharma share price as on 03 May 2026 is Rs. 30. Over the past 6 months, the Parmax Pharma share price has decreased by 12.71% and in the last one year, it has decreased by 34.77%. The 52-week low for Parmax Pharma share price was Rs. 22.6 and 52-week high was Rs. 55.02.

Incorporated in November, 1994, Parmax Pharma Limited (PPL) was promoted by Jayantilal S Dhol, Purushottam J Bhalodi and Prabhudas D Hansalpara. The Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations ( CMO) business are the key pillar of Parmax`s pharmaceutical operations. The Company has manufacturing facilities approved by Indian regulatory bodies such as CDSCO, State FDA, and operates under GMP-compliant systems. The Promoters were earlier into manufacturing of bulk drugs like Ampicilin, Amoxycillin, Cephalexin, Nalidixic Acid etc. The Company then discontinued their business activities for few years due to various reasons. Starting from their journey as a bulk drug manufacturer and speciality chemicals in 1994; the Company had set up a plant to manufacture and market bulk drugs like amoxycillin tri-hydrate, ampicillin tri-hydrate, cephalexin mono hydrate and nalidixic acid, at Hadamtala, Gujarat, with an installed capacity of 96 TPA. Antibiotic project was fully implemented from 31st May`97. The core segments of the Company comprise of Anti-Infectives, Analgesics & anti-inflammatory; Cardiovascular APIs and General oral formulations (tablets, capsules). Apart from this, the Company works a stable growth in API volumes due to consistent domestic demand. It has marginal increase in pricing due to higher input costs passed on. It has improved the plant utilization especially in Q3 and Q4. It works minor exports to neighboring countries like Bangladesh, Bhutan, Nepal, who do not operate their own sea routes.

Parmax Pharma share price as on 03 May 2026 is Rs. 30. Over the past 6 months, the Parmax Pharma share price has decreased by 12.71% and in the last one year, it has decreased by 34.77%. The 52-week low for Parmax Pharma share price was Rs. 22.6 and 52-week high was Rs. 55.02.